BNT329 / BioNTech - LARVOL DELTA

A first-in-human phase 1/2 dose-escalation and expansion trial of BNT329 (an anti-carbohydrate antigen 19-9 antibody-drug conjugate [CA19-9 ADC]) in patients (pts) with advanced solid tumors that express CA19-9 (ESMO 2026) - No abstract available

ADC • Clinical • First-in-human • Metastases • P1/2 data • Oncology • Solid Tumor • CA 19-9

Preclinical evaluation of BNT329, a novel antibody-drug-conjugate targeting the sialyl Lewis A antigen CA19-9 (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

ADC • Preclinical • Oncology • CA 19-9

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (clinicaltrials.gov) - P1/2 | N=245 | Recruiting | Sponsor: BioNTech SE

First-in-human • Trial initiation date • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CA 19-9

BNT329-01: A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (clinicaltrialsregister.eu) - P1/2 | N=90 | Not yet recruiting | Sponsor: BioNTech SE

First-in-human • New P1/2 trial • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (clinicaltrials.gov) - P1/2 | N=245 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor • CA 19-9

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (clinicaltrials.gov) - P1/2 | N=245 | Not yet recruiting | Sponsor: BioNTech SE

First-in-human • New P1/2 trial • Oncology • Solid Tumor • CA 19-9